Breaking News

Catalent, Pharmacyclics Enter IMBRUVICA Supply Pact

Catalent to provide capsules for ongoing trials and commercial supply

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has signed an agreement with Pharmacyclics to provide drug product capsules of IMBRUVICA (Ibrutinib) for ongoing clinical trials as well as commercial supply. IMBRUVICA received approval on November 13th for treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This agreement follows a multi-year development and clinical manufacturing partnership for Pharmacyclics’ expedited NDA submission. Additionally, Catalent’s site in K...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters